California Cancer Reporting System Standards, Volume III

IF917: Primary Site, Morphology-Type, Beh ICD-O-3

OWNER

SEER

EDIT SETS

California Hospital Transmit

Eureka Admission Level

Eureka Tumor Level

FIELDS

Over-ride Site/Type  [NAACCR #2030]

Primary Site  [NAACCR #400]

Behavior Code ICD-O-3  [NAACCR #523]

Histologic Type ICD-O-3  [NAACCR #522]

TABLE

IF25 3.DBF

IF25 REF.DBF

MESSAGE

1. IF917: Primary Site [value] and Histologic Type ICD-O-3 [value] conflict.

specification

This edit is skipped if:

• Histologic Type ICD-O-3 is blank

If the case has already been reviewed and accepted as coded (Over-ride Site/Type = 1) no further editing is done.

The SEER Site/Histology Validation List (see SEER web site) designates all histologies/behaviors that do not require review for each site. Any site/histology/behavior combination not in the Site/Histology Validation List will be accepted only if the case has been reviewed, accepted as coded, and Over-ride--Site/Type = 1. All other combinations will generate the message "Incompatible site and morphology". Since basal and squamous cell carcinomas of non-genital skin sites are not reportable to SEER, these site/histology combinations do not appear on the validation list.

The Site/Histology Validation List contains those histologies commonly found in the specified primary site. Histologies that occur only rarely or never may not be included. Review of these rare combinations often results in changes to the primary site and/or morphology, rather than a decision that the combination is correct. The over-ride flag should not be set to 1 if the primary site or histologic type are changed to a combination that will pass the edit. However, if upon review the site/type combination is found to be accurate and in conformance with coding rules, it may be left as coded and the Over-ride--Site/Type flag coded to 1.

ADDITIONAL INFORMATION:

This edit forces review of atypical site-type combinations. Combinations not requiring review are presented, by primary site, in the "SEER Site/Histology Validation List". This edit does not imply that there are errors but rather that the combination of site and histology are so unusual that they should be checked to ensure that they correctly reflect what is in the medical record. Resolution of discrepancies may require inspection of the abstracted text, either online or as recorded on a paper abstract. Review of the original medical record may be necessary.

Review of these cases requires investigating whether a) the combination is biologically implausible, or b) there are cancer registry coding conventions that would dictate different codes for the diagnosis. The following resources can be checked:

Current oncology and pathology textbooks

Current medical journal articles, e.g., via MEDLINE

Pathologist advisors to the registry

If upon review it is decided that the case is appropriately coded, set the Over-ride--Site/Type flag to 1 so that the case will not be flagged for review when the edit is run again.

historical changes